RICHARD M SIEGEL
Medical Practice in Bethesda, MD
License number
Pennsylvania MD056773L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Bethesda, MD 20817
Pennsylvania
Pennsylvania
Personal information
See more information about RICHARD M SIEGEL at radaris.comName
Address
Phone
49 Ring Neck Dr, Harrisburg, PA 17112
6122 Reisterstown Rd, Baltimore, MD 21215
5610 Roosevelt St, Bethesda, MD 20817
367 Harshaw Dr, Chester Sprgs, PA 19425
3831 Perry Hall Rd, Perry Hall, MD 21128
Professional information
Richard Siegel, Bethesda MD
Work:
National Institutes of Health
9000 Rockville Pike, Bethesda, MD 20892
9000 Rockville Pike, Bethesda, MD 20892
Dr. Richard M Siegel, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
9000 Rockville Pike SUITE 10, Bethesda 20892
Certifications:
Internal Medicine, 1996, Rheumatology, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1993
Perelman School of Medicine University of Pennsylvania
Graduated: 1993
Blockade Of Tl1A-Dr3 Interactions To Ameliorate T Cell Mediated Disease Pathology And Antibodies Thereof
US Patent:
2012026, Oct 18, 2012
Filed:
Mar 13, 2012
Appl. No.:
13/419203
Inventors:
RICHARD M. SIEGEL - BETHESDA MD, US
FRANCOISE MEYLAN - BETHESDA MD, US
YUN-JEONG SONG - ROCKVILLE MD, US
FRANCOISE MEYLAN - BETHESDA MD, US
YUN-JEONG SONG - ROCKVILLE MD, US
International Classification:
A61K 39/395, A61P 11/06, A61P 25/00, A61P 29/00, G01N 21/64, A61P 3/10, A61P 37/06, A61P 37/00, G01N 33/566, C40B 30/04, C07K 16/24, A61P 1/00
US Classification:
4241341, 4241301, 4241581, 53038823, 5303873, 436501, 506 9, 435 724, 435 792
Abstract:
Provided are methods and compositions for treating inflammatory autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).
Blockade Of Tl1A-Dr3 Interactions To Ameliorate T Cell Mediated Disease Pathology
US Patent:
2011021, Sep 8, 2011
Filed:
Jan 10, 2008
Appl. No.:
11/972395
Inventors:
RICHARD M. SIEGEL - Bethesda MD, US
FRANCOISE MEYLAN - Bethsda MD, US
FRANCOISE MEYLAN - Bethsda MD, US
International Classification:
A61K 39/395, A61K 38/02, A61K 38/10, A61P 11/06, A61P 19/02, A61P 3/10, A61P 1/00, A61P 29/00, G01N 33/68
US Classification:
4241581, 514 11, 514 215, 436501
Abstract:
Provided is a method and compositions for of treating an inflammatory or autoimmune disease in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).